Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678242 | 0.94 | CHEK1 (0.51) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL27604790 | 0.84 | CHEK1 (0.35) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL1542059 | 0.83 | IKBKE (0.53) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL24268644 | 0.81 | CHEK1 (0.51) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL1982431 | 0.81 | CHEK1 (0.55) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL30073737 | 0.81 | CHEK1 (0.51) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL26204290 | 0.80 | EGFR (0.43) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL21796872 | 0.79 | IKBKE (0.53) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL33525614 | 0.77 | CHEK1 (0.43) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL16977664 | 0.77 | MAPK14 (0.47) | CHEK1AURKADAPK3CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1809282-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | CHEK1 375/4885AURKA 2194/4885DAPK3 213/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CHEK1 657/4885AURKA 710/4885DAPK3 329/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHEK1 4336/4885AURKA 4715/4885DAPK3 4553/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | CHEK1 3830/4885AURKA 4357/4885DAPK3 4667/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | CHEK1 375/4885AURKA 2194/4885DAPK3 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.